Cancer Policy Former FDA Commissioner Scott Gottlieb speaks out against CDC vaccine panel December 12, 2025Vol.51 No.45By Sara Willa Ernst
Regulatory News Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulationsBIO calls for the end of “constant turmoil,” urges the administration to “right the ship” December 05, 2025Vol.51 No.44By Paul Goldberg
Cancer Policy Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend” December 05, 2025Vol.51 No.44By Jacquelyn Cobb
Cancer Policy FDA releases draft guidance on reducing testing on non-human primates for monoclonal antibodies December 05, 2025Vol.51 No.44By Jacquelyn Cobb
Drugs & Targets FDA approves Keytruda and Keytruda Qlex + Padcev as perioperative treatment cisplatin-ineligible bladder cancer December 05, 2025Vol.51 No.44
Drugs & Targets FDA grants 501(k) clearance for Vanquish System for prostate tissue ablation in intermediate risk prostate cancer December 05, 2025Vol.51 No.44
Drugs & Targets FDA approves durvalumab + FLOT for resectable gastric or gastroesophageal junction adenocarcinoma December 05, 2025Vol.51 No.44
Guest Editorial My introduction to, and lessons learned from, Rick Pazdur November 21, 2025Vol.51 No.43By Mikkael A. Sekeres
Cancer Policy Makary, Prasad describe FDA’s new “plausible mechanism pathway” to get bespoke therapies to market sans RCT November 21, 2025Vol.51 No.43By Jacquelyn Cobb
